

VPT

PATENTES

BIOTECNOLOGÍA SANITARIA

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune

36



**Vigilancia
Tecnológica**
2º trimestre 2022

NIPO: 116-19-008-3

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM) y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el

mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular. A través del número de publicación de cada patente, un enlace permite consultar el documento completo e incluso poder disponer de una traducción de la descripción realizada con la herramienta Patent translate.


También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente [formulario de suscripción](#).

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.


Contenido




**DEGENERACIÓN
MACULAR**



DIABETES



SISTEMA NERVIOSO



SISTEMA INMUNE

Degeneración Macular

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022113887	KYOTO PREFECTURAL PUBLIC UNIV CORP [JP]	Method for assessing inflammatory retinal disease, inflammatory retinal disease therapeutic, and screening method for inflammatory retinal disease therapeutics
WO2022092326	HARA HIDEAKI [JP]; SHIMAZAWA MASAMITSU [JP]; NAKAMURA SHINSUKE [JP]	GDF15 modulator for use in inhibition of ocular tissue fibrosis
WO2022086039	SIGNET BIOTECH INC [KR]	Composition for preventing or treating macular degeneration comprising peptide for inhibiting fas signaling
WO2022073072	IMPLICIT BIOSCIENCE LTD [AU]	Methods and agents for the treatment of ocular disease
WO2022070142	GENEROATH CO LTD [KR]	Methods of treating age-related macular diseases using AIMP2-DX2 and optionally a target sequence for miR-142 and compositions thereof
WO2022054925	RIKEN [JP]; SUMITOMO DAINIPPON PHARMA CO LTD [JP]	Complex containing neural retina-containing cell aggregates and matrix, and method for manufacturing same
WO2022084355	BOEHRINGER INGELHEIM INT [DE]	Agonistic TrkB binding molecules for the treatment of eye diseases
WO2022084354	BOEHRINGER INGELHEIM INT [DE]	Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases
WO2022074370	UNIV BRISTOL [GB]	IL-33 therapy for use in the treatment, prevention or management of age-related macular degeneration (AMD)
WO2022058447	UNIV MANCHESTER [GB]	Complementome assay
WO2022049259	CUREBIOTECH GMBH [DE]	Pigment epithelium-derived factor (PEDF) for use in treatment of macular degeneration or choroidal neovascularisation
WO2022051489	BETH ISRAEL DEACONESS MEDICAL CT INC [US]	Conformation-specific antibodies that bind tau protein and uses thereof
WO2022059736	RESTORE VISION INC [JP]	Composition for treating or preventing diseases, disorders, or conditions associated with endoplasmic reticulum stress or all-trans-retinal, protecting retinal thickness, or suppressing reduction in retinal thickness or progress of reduction in retinal thickness

Diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022117044	SUNSHINE LAKE PHARMA CO LTD [CN]	GLP-1/GCG dual receptor agonist polypeptide and fusion protein thereof
WO2022107877	ORIZURU THERAPEUTICS INC [JP]	Maturation agent
WO2022107853	UNIV KAGOSHIMA [JP]	Low-dose hepatocyte growth factor gene therapy for diabetes
WO2022104394	UNIV LELAND STANFORD JUNIOR [US]	Systems and methods for diagnostic assessment and treatment of insulin resistance and hyperglycemia
WO2022099123	MEDICAL COLLEGE WISCONSIN INC [US]	Peptide inhibitors of human mitochondrial fission protein 1 and methods of use
WO2022094614	UNIV CALIFORNIA [US]; UNIV BRUXELLES [BE]; UNIV BRUSSEL VRIJE [BE]	Anti-DPP6 chimeric antigen receptor bearing regulatory T cells
WO2022092546	GIL MEDICAL CT [KR]	Pharmaceutical composition for prevention or treatment of metabolic disease containing bone morphogenetic protein 10 as active ingredient
WO2022089639	SHENZHEN PROTGEN LTD [CN]	Use of human serum albumin in treatment of diseases
WO2022085900	MEDISPAN CO LTD [KR]; UNIV NAT CHONNAM IND FOUND [KR]	Composition for preventing or treating non-alcoholic fatty liver disease or metabolic syndrome, comprising flagellin fusion proteins
WO2022087385	UNIV INDIANA TRUSTEES [US]	Molecular designs of glucose-responsive and glucose-cleavable insulin analogues
WO2022080986	1/1HANMI PHARM CO LTD [KR]	GLP-1/GIP dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same
WO2022076117	PROTEIN GENOMICS INC [US]	Biomimetic wound healing devices and related methods of treating diabetic wounds
WO2022075660	RHEE HAE IK [KR]	Novel <i>Bacillus coagulans</i> CC strain producing α -glucosidase inhibitor
WO2022073211	CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE CHINESE ACAD OF SCIENCES [CN]	Method for inducing differentiated cells into pluripotent endoderm stem cells and application thereof
WO2022076673	UNIV CALIFORNIA [US]	Immunoengineering biomaterials for treatment of graft rejection
WO2022068920	BEIJING QL BIOPHARMACEUTICAL CO LTD [CN]	Polypeptide conjugates and methods of uses
WO2022065859	RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV [KR]	Method for direct reprogramming from somatic cells into pancreatic beta cells by using microRNA, and differentiation composition
WO2022066212	WEI YANG [US]	A long-lasting GLP1 analogue drug for type-2 diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022061962	SHANGHAI INST OF NUTRITION AND HEALTH CHINESE ACADEMY OF SCIENCES [CN]	Method for effectively intervening diabetes by using L-type amino acid transporter inhibitor or antagonist
WO2022059736	RESTORE VISION INC [JP]	Composition for treating or preventing diseases, disorders, or conditions associated with endoplasmic reticulum stress or all-trans-retinal, protecting retinal thickness, or suppressing reduction in retinal thickness or progress of reduction in retinal thickness
WO2022060178	UNIV KOREA RES & BUS FOUND [KR]	Method for prediction of recurrence or prognosis of diabetic foot ulcer by using specific methylation of gene
WO2022056127	ALNYLAM PHARMACEUTICALS INC [US]	IRNA compositions and methods for silencing growth factor receptor bound protein 10 (GRB10) or growth factor receptor bound protein 14 (GRB14) in the liver
WO2022056014	CUE BIOPHARMA INC [US]	MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
WO2022054029	CELROS BIOTECH [KR]	SH3YL1 antibodies, compositions comprising the same, and vectors and uses thereof
WO2022047517	FLOREY INST FOR NEUROSCIENCE AND MENTAL HEALTH [AU]	Derivatisation of peptides and proteins
WO2022048577	HUASHAN HOSPITAL FUDAN UNIV [CN]	Use of monoclonal antibody against human EMC10 in preparation of products for preventing and/or treating metabolic diseases
WO2022047367	VITRUVIAN MEDICAL DEVICES INC [US]; OCTAPHARMA AG [CH]	Storage stable films comprising fibrin and/or fibrinogen
WO2022044059	AL DABET MOHD MOHANAD [JO]	Micro-RNA marker of diabetic nephropathy
WO2022112251	GRIFOLS WORLDWIDE OPERATIONS LTD [IE]	Wound healing
WO2022096736	EMBARK BIOTECH APS [DK]	Compounds and their use in treatment of tachykinin receptor mediated disorders
WO2022084490	BOEHRINGER INGELHEIM INT [DE]	Anti-sema3A antibodies and their uses for treating a thrombotic disease of the retina
WO2022066847	ALNYLAM PHARMACEUTICALS INC [US]	Dipeptidyl peptidase 4 (DPP4) iRNA compositions and methods of use thereof
WO2022043518	NOVO NORDISK AS [DK]	Method for screening in vitro population of stem cell derived beta like cells and novel markers thereof
WO2022067334	UNIV CHICAGO [US]	Anti-inflammatory cytokines and methods of use
WO2022036270	UNIV COLORADO REGENTS [US]	Phospholipid bilayers catalytically promote protein refolding, inhibit and reverse protein aggregate formation, and methods of treating neurodegenerative diseases using the same

Sistema Nervioso

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022120373	AMGEN INC [US]	TREM2 agonist biomarkers and methods of use thereof
WO2022115951	UNIV HEALTH NETWORK [CA]	Methods and uses for Ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies
WO2022114906	UNIV SEJONG IND ACAD COOP FOUO [KR]; UNIV ULSAN FOUND IND COOP [KR]; ASAN FOUND [KR]	Novel pharmaceutical composition for treating neurodegenerative diseases
WO2022114920	PCL INC [KR]	Novel biomarker for diagnosis of Alzheimer's disease, discovered from blood-derived exosomes, and method for diagnosing Alzheimer's disease using same
WO2022115535	PREVAIL THERAPEUTICS INC [US]	Gene therapies for neurodegenerative disease
WO2022114526	SEOUL NAT UNIV R&DB FOUNDATION [KR]; UNIV CHOSUN IACF [KR]; NEUROZEN INC [KR]	Single nucleotide polymorphism marker for predicting risk of Alzheimer's disease and use thereof
WO2022114154	UNIV TOKYO [JP]	Method for detecting mild cognitive impairment and mild Alzheimer's disease
WO2022109758	SHEN ZHEJING [CN]	Application of proteolytic enzyme of pit viper in treatment of Alzheimer's disease
WO2022109376	UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS [US]	Compositions and methods for suppressing MSUT2
WO2022108950	ILIAD BIOTECHNOLOGIES LLC [US]	Treatment and prevention of neuropathology associated with neurodegenerative diseases
WO2022102654	MCBI INC [JP]	Combination of biomarkers, and method for detecting cognitive dysfunction or risk thereof by using said combination
WO2022104011	YUMANITY THERAPEUTICS INC [US]	Methods for the treatment of neurological disorders
WO2022103064	RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV [KR]	Composition comprising corticotropin-releasing hormone as active ingredient for promoting neurosphere formation
WO2022102787	UNIV KYOTO [JP]	Method of producing astrocytes from pluripotent stem cells
WO2022097727	SUMITOMO PHARMA CO LTD [JP]; LUXNA BIOTECH CO LTD [JP]	Regulator for expression and/or function of RPS25 gene
WO2022098699	VOYAGER THERAPEUTICS INC [US]	Compositions and methods for the treatment of tauopathy
WO2022098078	TOOLGEN INC [KR]	Prion-Fc region fusion protein and use thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022098110	S BIOMEDICS [KR]	Pharmaceutical composition for treating degenerative brain disease, including neural precursor cells derived from pluripotent stem cells
WO2022091086	HADASIT MED RES SERVICE [IL]; NEUROGENESIS LTD [IL]	Mesenchymal stem cells and their culture
WO2022089639	SHENZHEN PROTGEN LTD [CN]	Use of human serum albumin in treatment of diseases
WO2022087694	FRANS EDUARDO [BR]	Saliva-based Alzheimer's diagnosis using the lateral flow assay method
WO2022086753	UNIV DUKE [US]	Compositions and methods relating to Alzheimer's disease
WO2022087104	CHAN ZUCKERBERG BIOHUB INC [US]; UNIV CALIFORNIA [US]; SCHAFFER DAVID V [US]; ZHU DANQING [US]; NOWAKOWSKI TOMASZ J [US]; SCHMUNK GALINA [US]	Adeno-associated virus virions and methods of use thereof
WO2022082199	PLURIPOTENT DIAGNOSTICS CORP [US]	Method for detecting amyotrophic lateral sclerosis
WO2022081245	THE METHODIST HOSPITAL SYSTEM [US]	Compositions and methods for increasing lymphangiogenesis
WO2022075337	UNIV CHIBA NAT UNIV CORP [JP]	Novel anti-sugar chain antibody and use thereof
WO2022075243	PUBLIC UNIV CORP YOKOHAMA CITY UNIV [JP]	Schizophrenia biomarker
WO2022075354	OKINAWA INST SCIENCE & TECH SCHOOL CORP [JP]	A method for obtaining an index for the diagnosis of Alzheimer's disease (AD)
WO2022072709	UNIV CALIFORNIA [US]	Compositions and methods for modulating TCF4 gene expression and treating Pitt Hopkins syndrome
WO2022072255	MERCK SHARP & DOHME [US]; SEVY ALEXANDER MARIO [US]; CHEN MING TANG [US]	Binding proteins and antigen binding fragments thereof that bind Abeta
WO2022071591	O FORCE CO LTD [JP]	Amyloid- β aggregation inhibitor, pharmaceutical composition for amyloid- β aggregation diseases, and use application of same
WO2022072308	NEUEXCELL THERAPEUTICS INC [US]	NeuroD1 vector
WO2022072325	NEUEXCELL THERAPEUTICS INC [US]	NeuroD1 combination vector
WO2022071696	SEOUL NAT UNIV R&DB FOUNDATION [KR]	Peptide for preventing or treating neurodegenerative diseases and pharmaceutical composition comprising same
WO2022070798	HASHIMOTO YASUHIRO [JP]	Combined markers for differentiating pathological conditions of Alzheimer's disease and method of differentiating pathological conditions of Alzheimer's disease using same
WO2022070141	GENEROATH CO LTD [KR]	Methods of treating neuronal diseases using AIMP2-DX2 and optionally a target sequence for miR-142 and compositions thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022066956	IONIS PHARMACEUTICALS INC [US]	Compounds and methods for reducing APOE expression
WO2022066723	CEDARS SINAI MEDICAL CENTER [US]	Complex microfluidic models for ALS including NF biomarkers for ALS research and drug development
WO2022067334	UNIV CHICAGO [US]	Anti-inflammatory cytokines and methods of use
WO2022065899	HANMI PHARM IND CO LTD [KR]	Therapeutic use of long-acting conjugate of triple agonist acting on all of glucagon, GLP-1 and GIP receptors against multiple sclerosis
WO2022066911	SEELOS THERAPEUTICS INC [US]	Compositions and methods for inhibiting alpha-synuclein aggregation
WO2022065568	PROBIONIC INC [KR]	Composition for prevention or treatment of Alzheimer's disease comprising <i>Lactobacillus sakei</i> Probio-65
WO2022061812	INNATEPHAGO PHARMACEUTICS PTY LTD [CN]	Use of glatiramer acetate in preparation of Aβ42 toxicity inhibitor and scavenger
WO2022056619	UNIV MANITOBA [CA]	Use of Nrg-1beta1 for detection and/or treatment of multiple sclerosis
WO2022060488	OTHAIR PROTHENA LTD [IE]; BARBOUR ROBIN [US]; KINNEY GENE [US]; ZAGO WAGNER [US]	Multiepitope vaccine for the treatment of Alzheimer's disease
WO2022061378	ASKLEPIOS BIOPHARMACEUTICAL INC [US]	Methods for treating neurological disease
WO2022060424	OTHAIR PROTHENA LTD [IE]; BARBOUR ROBIN [US]; KINNEY GENE [US]; ZAGO WAGNER [US]	B-amyloid vaccine for the treatment of Alzheimer's disease
WO2022060857	BIOGEN MA INC [US]	Compositions and methods for treating amyotrophic lateral sclerosis (ALS) with AAV-miR-SOD1
WO2022054801	OHARA PHARMACEUTICAL CO LTD [JP]	siRNA and use thereof
WO2022054795	UNIV OSAKA [JP]	Immunogenic composition targeting phosphorylated tau protein
WO2022052738	SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE [CN]	Application of circular RNA Cwc27 down-regulator in preparation of drug for preventing and/or treating Alzheimer's disease
WO2022055320	GENEROATH CO LTD [KR]	Adeno-associated virus vector for targeted gene delivery
WO2022051489	BETH ISRAEL DEACONESS MEDICAL CT INC [US]	Conformation-specific antibodies that bind tau protein and uses thereof
WO2022036270	UNIV COLORADO REGENTS [US]	Phospholipid bilayers catalytically promote protein refolding, inhibit and reverse protein aggregate formation, and methods of treating neurodegenerative diseases using the same
WO2022084355	BOEHRINGER INGELHEIM INT [DE]	Agonistic TrkB binding molecules for the treatment of eye diseases

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022084354	BOEHRINGER INGELHEIM INT [DE]	Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases
WO2022100920	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIV RAMON Y CAJAL [ES]	Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
WO2022056528	LONGEVERON INC [US]	Treatment of Alzheimer's disease with allogeneic mesenchymal stem cells
WO2022093375	MASSACHUSETTS INST TECHNOLOGY [US]	Multicellular integrated brain tissue in neurological diseases
EP4008789	ECOLE POLYTECHNIQUE FED LAUSANNE EPFL [CH]	Bicistronic AAV vector for RNA interference in ALS
WO2022093274	BASELINE GLOBAL INC [US]; RAI BALWANT [DK]; KAUR JASDEEP [DK]	Methods, systems, and kits for prediction, detection, monitoring, and treatment of Alzheimer's disease
WO2022089767	UCB BIOPHARMA SRL [BE]	Use of anti-TREM1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
WO2022098661	KEYSTONE BIO INC [US]	Antigen-binding molecules that bind to <i>Porphyromonas gingivalis</i>
WO2022031598	UNIV CALIFORNIA [US]; THE STEADMAN CLINIC & STEADMAN PHILIPPON RES INSTITUTE [US]	Composition and method for treating neuropathy
WO2022076712	ZOETIS SERVICES LLC [US]	Anti-NGF antibodies and methods of use thereof

Sistema Inmune

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022119842	CEDARS SINAI MEDICAL CENTER [US]	Methods and systems of stratifying inflammatory disease patients
WO2022108522	SENGENICS CORP PTE LTD [SG]; UNIV MEDICAL HOSPITAL CHINA	Biomarkers for predicting immunogenicity and therapeutic responses to adalimumab in rheumatoid arthritis patients
WO2022109022	SKYHAWK THERAPEUTICS INC [US]	RNA-targeting splicing modifiers for treatment of MDA5-associated conditions and diseases
WO2022108982	UNIV YALE [US]	Targeting host-bacteria interactions for the treatment of microbiota-mediated diseases
WO2022108165	ONCOINSIGHT CO LTD [KR]	Method for producing exosomes isolated from induced pluripotent stem cell-derived mesenchymal stem cells, and use thereof
WO2022098790	BENAROYA RES INSTITUTE AT VIRGINIA MASON [US]	Tenascin-C autoantigenic epitopes in rheumatoid arthritis
WO2022098124	PROSTEMICS CO LTD [KR]	Novel <i>Lactobacillus sp.</i> strain and use of extracellular vesicles derived from same strain
WO2022095715	SHANGHAI SEME CELL TECH CO LTD [CN]	Use of cell-free fat extract for treating ulcerative colitis
WO2022099317	UNIV COLORADO REGENTS [US]	Bacterial biomarker for rheumatoid arthritis and related materials and methods
WO2022094437	ONESKIN INC [US]; UNIAO BRASILEIRA DE EDUCACAO CATOLICA [BR]; UNIV CATOLICA DE BRASILIA [BR]	Polypeptides having anti-inflammatory effects and uses thereof
WO2022092964	BIOME INC [KR]	Composition for preventing or treating inflammatory bowel disease
WO2022086777	GUSTO GLOBAL LLC [US]	Microbial-based compositions for systemic inflammation control
WO2022086276	CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]	Pharmaceutical composition for prevention or treatment of rheumatoid arthritis, comprising, as active ingredient, stem cells having expression of specific genes increased or decreased therein
WO2022086197	GOOD T CELLS INC [KR]	Cell surface antigen of activated immune cell and various uses thereof
WO2022085456	SONE FARM CO LTD [JP]	Composition for inflammatory bowel disease

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022080989	HANMI PHARM IND CO LTD [KR]	Pharmaceutical composition comprising glucagon/GLP-1/GIP triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
WO2022081794	TAVOTEK BIOTHERAPEUTICS HONG KONG LTD [CN]	Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
WO2022082019	PANDION OPERATIONS INC [US]	Kidney targeted immunotolerance
WO2022082014	PANDION OPERATIONS INC [US]	Skin targeted immunotolerance
WO2022080984	HANMI PHARM IND CO LTD [KR]	GIP derivative, long-acting conjugate thereof, and pharmaceutical composition comprising same
WO2022080985	HANMI PHARM IND CO LTD [KR]	Pharmaceutical composition for preventing or treating lupus-related diseases comprising GIP derivative or long-acting conjugate thereof
WO2022074603	JANSSEN BIOTECH INC [US]	Method for treating Crohn's disease with anti-IL12/IL23 antibody
WO2022075474	UNIV KEIO [JP]; TAKEDA PHARMACEUTICALS CO [JP]	Therapeutic agent for immune/inflammatory disease
WO2022072576	CELGENE CORP [US]	Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies
WO2022072282	ORTHOTROPHIX INC [US]	Method to identify responders to osteoarthritis therapeutics
WO2022072156	ORTHOTROPHIX INC [US]	Hard tissue therapeutics
WO2022072508	DREN BIO INC [US]	Anti-CD94 antibodies and methods of use thereof
WO2022065957	CHUNLAB INC [KR]	Composition for diagnosis or treatment of inflammatory diseases, comprising microorganism
WO2022059766	CHUGAI PHARMACEUTICAL CO LTD [JP]	Anti-HLA-DQ2.5 antibody and its use for the treatment of celiac disease
WO2022055971	UNIV DUKE [US]	Methods for reprogramming target cells
WO2022039455	RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV [KR]	Antibody or antigen-binding fragment thereof that specifically binds to IL-33
WO2022038560	NOVMETAPHARMA CO LTD [KR]	Method for treating inflammatory bowel diseases
WO2022016375	SHENZHEN INST ADV TECH [CN]	Ectopic endometrium recognition polypeptide, and derivative and use thereof
WO2022094177	UNIV WASHINGTON [US]; UNIV CALIFORNIA [US]	Compositions and methods for treating celiac sprue disease
WO2022094275	SQUIBB BRISTOL MYERS CO [US]	Fusion proteins for the treatment of disease
WO2022103321	SYNBIOTICS AB [SE]	Synbiotic composition
WO2022101322	INTRACT PHARMA LTD [GB]	Pharmaceutical composition comprising a peptide as active ingredient

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2022077021	PFIZER [US]; CHILDRENS MEDICAL CENTER [US]	CD1A antibodies and uses thereof
WO2022076573	XENCOR INC [US]	Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematosus (SLE)
WO2022073038	ABBVIE INC [US]; ABBVIE GLOBAL ENTPR LTD [GB]	Interleukin-22 (IL-22) fusion proteins and uses thereof
WO2022090144	AMYRA BIOTECH AG [CH]	Dipeptidylpeptidase and leucine aminopeptidase polypeptide variants
WO2022074123	ASTRAZENECA AB [SE]	Treatment of flares in lupus
WO2022069907	MICROBIOTICA LTD [GB]	Therapeutic bacterial composition
WO2022079036	ALMIRALL SA [ES]	Bispecific molecules and methods of treatment using the same
WO2022061061	BOEHRINGER INGELHEIM INT [DE]	Use of anti-CD40 antibodies for treatment of inflammatory conditions
WO2022053673	LIMMATECH BIOLOGICS AG [CH]	Fab sialylation of antibodies
WO2022049273	INST NAT SANTE RECH MED [FR]; UNIV TOULOUSE III - PAUL SABATIER [FR]; ECOLE NAT VETERINAIRE DE TOULOUSE [FR]; INSTITUT NATIONAL DE RECH POUR L'AGRICULTURE L'ALIMENTATION ET L'ENVIRONNEMENT [FR]	Methods of treatment of inflammatory bowel diseases
WO2022089727	AMYRA BIOTECH AG [CH]	Dipeptidylpeptidase and leucine aminopeptidase polypeptide variants
WO2022094614	UNIV CALIFORNIA [US]; UNIV BRUXELLES [BE]; UNIV BRUSSEL VRIJE [BE]	Anti-DPP6 chimeric antigen receptor bearing regulatory T cells
WO2022075337	UNIV CHIBA NAT UNIV CORP [JP]	Novel anti-sugar chain antibody and use thereof
WO2022067334	UNIV CHICAGO [US]	Anti-inflammatory cytokines and methods of use
WO2022076712	ZOETIS SERVICES LLC [US]	Anti-NGF antibodies and methods of use thereof
WO2022075693	POSTECH RES & BUSINESS DEV FOUND [KR]	Development and application of polymer-coated gold nanoparticle-aptamer nanoconstruct having sensitivity to reactive oxygen species
WO2022053715	ICHNOS SCIENCES SA [CH]	Antibodies that bind to IL1RAP and uses thereof
WO2022109399	CUE BIOPHARMA INC [US]	TGF-beta polypeptides
WO2022098846	DARTMOUTH COLLEGE [US]	Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
WO2022088342	SUZHOU GENEPHARMA CO LTD [CN]	siRNA targeting FOXP3 gene and modification method therefor
WO2022109341	DORIAN THERAPEUTICS INC [US]	Compounds for treatment of osteoarthritis

Noticias

PUBLICACIÓN DEL INFORME "LA OEPM EN CIFRAS 2021"



La Oficina Española de Patentes y Marcas, O.A. (OEPM) ha hecho públicos los datos y cifras de patentes, modelos de utilidad, marcas, nombres comerciales, diseños e Informes Tecnológicos de Patentes (ITP), relativos al año 2021, en su informe anual denominado "La OEPM en cifras".

Las fuentes utilizadas para la elaboración del folleto corresponden a las Bases de Datos de la OEPM, así como de la Oficina Europea de Patentes (OEP), la Organización Mundial de la Propiedad Intelectual (OMPI) y la Oficina de Propiedad Intelectual de la Unión Europea (EUIPO).

[Más información](#)

[La OEPM en cifras 2021](#)

ELENA GARCÍA ARMADA, PREMIO POPULAR AL INVENTOR EUROPEO 2022

El pasado 21 de junio de 2022, la Oficina Europea de Patentes (EPO) dio a conocer los ganadores de la decimosexta edición de los Premios al Inventor Europeo, galardones que cada año concede a personas destacadas en Europa y fuera de ella que, con sus innovaciones, contribuyen al desarrollo tecnológico, al crecimiento económico y a la mejora de la sociedad.



La investigadora del Consejo Superior de Investigaciones Científicas (CSIC), Elena García Armada, recibió el Premio Popular al Inventor Europeo 2022 por su pionero exoesqueleto adaptable. El exoesqueleto permite caminar a los niños en silla de ruedas durante las sesiones de rehabilitación y reduce la degradación muscular y las complicaciones médicas. La investigadora del CSIC recibe así uno de los reconocimientos internacionales más relevantes en el ámbito de la innovación.

[Más información](#)

[Premios al Inventor Europeo](#)

I EDICIÓN DE LOS PREMIOS A LA MEJOR INVENCIÓN PROTEGIDA POR PROPIEDAD INDUSTRIAL

El pasado 1 de junio se celebró la gala de entrega de galardones de la Primera Edición de los Premios a la Mejor Invención Protegida por Propiedad Industrial, convocada por la Oficina Española de Patentes y Marcas, O.A. (OEPM), en los jardines de la sede madrileña de la Escuela de Organización Industrial (EOI).



El acto fue presidido por la Sra. Ministra de Industria, Comercio y Turismo, Reyes Maroto Illera, acompañada del Subsecretario del Ministerio y Presidente de la OEPM, Pablo Garde Lobo. Ambos destacaron la importancia de la Propiedad Industrial como activos intangibles, y el compromiso del gobierno por la innovación.

El objetivo de estos premios es distinguir la protección de resultados de investigación mediante Patentes y Modelos de Utilidad concedidos en el año 2020 por la OEPM, reconociendo

así públicamente el valor de la I+D española protegida y posicionada competitivamente en el mercado. Con todo ello, el fin último perseguido no es otro que el de apoyar y fomentar la actividad investigadora, científica y tecnológica y premiar el carácter innovador de nuestros inventores como motor del desarrollo tecnológico de nuestra sociedad.

[Más información](#)

RECORDATORIO SOBRE LA PRESENTACIÓN DE SOLICITUDES DE PATENTES QUE CONTENGAN LISTAS DE SECUENCIAS DE NUCLEÓTIDOS Y AMINOÁCIDOS DE ACUERDO CON LA NORMA ST.26 DE LA OMPI

La Asamblea General de OMPI, que tuvo lugar entre los días 4 a 8 de octubre de 2021, aprobó que la fecha de transición generalizada a la Norma ST.26 de la OMPI a escala nacional, regional e internacional para la presentación de listas de secuencias de nucleótidos y aminoácidos contenidas en solicitudes de patentes quedaba establecida en el día 1 de julio de 2022. Por tanto, es esta Norma ST.26 de la OMPI la que debe utilizarse para divulgar secuencias de nucleótidos y aminoácidos en las solicitudes de patentes presentadas en fecha igual o posterior al 1 de julio de 2022.

En comparación con la anterior Norma ST.25 de la OMPI, la nueva norma incluye tipos de secuencias adicionales y es más coherente con los requisitos de las principales bases de datos de secuencias. Con ello se pretende ayudar tanto en la preparación de los listados de secuencias como en la disponibilidad de datos de secuencias para su búsqueda.

Es muy importante recordar que la fecha de presentación de la solicitud de patente es la fecha de referencia que determina si en una solicitud se aplica la Norma ST.25 o la Norma ST.26, y no la fecha de prioridad.

Así pues, toda divulgación de secuencias en una solicitud presentada antes del 1 de julio de 2022 debe seguir cumpliendo con la norma ST.25, tanto en el momento de la presentación como con respecto a cualquier listado presentado posteriormente. Sin embargo, toda divulgación de secuencias en una solicitud presentada a partir del 1 de julio de 2022 debe cumplir con la Norma ST.26, incluso si la solicitud prioritaria contiene un listado de secuencias con formato de acuerdo con la Norma ST.25 de la OMPI.

[Más información](#)

